Jefferies raised the firm’s price target on AxoGen (AXGN) to $36 from $29 and keeps a Buy rating on the shares after the FDA approved the biologics license application for Avance. The firm expects approval with a broad label will support continued commercial coverage wins and surgeon adoption as well as enhance the competitive moat, the analyst tells investors. The firm sees a “favorable setup” in 2026 with upside risk to Street estimates on continued commercial coverage wins, a sales rep productivity ramp and a reimbursement catalyst, the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen announces FDA approval of Avance biologics license application
- AxoGen Secures FDA Approval for Avance Nerve Scaffold
- AxoGen initiated with an Outperform at Mizuho
- AxoGen price target raised to $26 from $25 at H.C. Wainwright
- AxoGen’s Strong Financial Performance and Strategic Advancements Justify Buy Rating